1322P Development and external validation of a novel four-gene-pair signature for predicting clinical response to anti-PD-1 immunotherapy of non-small cell lung cancer

Abstract

Immune-checkpoint inhibitors (ICIs) are characterised by durable responses and improved survival in patients with advanced non-small cell lung cancer (NSCLC). Unfortunately, only certain patients can benefit from immunotherapy, therefore a feasible tool is urgently needed to predict the patients who might benefit from ICIs in clinical practice.